<DOC>
	<DOC>NCT02815592</DOC>
	<brief_summary>The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.</brief_summary>
	<brief_title>Trial of BMS-986012 in Combination With Platinum and Etoposide</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Male and Females 18 years of age or older Pulmonary SCLC documented by histology or cytology Extensive disease (Stage IV) SCLC Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Prior systemic therapy for lung cancer Symptomatic brain metastases Grade 2 peripheral neuropathy Active or chronic infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV Other active malignancies or prior malignancy within 2 years Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>